Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Expression of Proprotein Convertase Subtilisin Kexin 9 in Patients With Rheumatoid Arthritis Combined Atrial Fibrillation

NCT05191342 is registered in ClinicalTrials.gov with First Affiliated Hospital of Harbin Medical University as lead sponsor.

NCT NCT05191342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05191342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Expression of Proprotein Convertase Subtilisin Kexin 9 in Patients With Rheumatoid Arthritis Combined Atrial Fibrillation
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Phase
Observational
Overall status
Unknown status
Start date
November 1, 2021
Completion date
November 1, 2022
Enrollment
75 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pcsk9